Skip to main content
. 2019 Mar 21;4(6):e125294. doi: 10.1172/jci.insight.125294

Figure 6. miR-1246 is overexpressed in CD44v6+ CSCs and is a prognostic biomarker for CRC.

Figure 6

(A) Expression of miR-1246 in CD44v6+ and CD44v6– sphere-derived cancer stem cells (SDCSCs) derived from HCT116 and HT29 cell lines (n = 3, Mann-Whitney U test). (B) Expression of miR-1246 in 5FUR and parental HCT116 cell line (n = 3, Mann-Whitney U test). (C) Correlation analysis between CD44v6 and miR-1246 expression in CRC tissue from clinical cohort 1. (D) miR-1246 expression in cancer tissues versus adjacent normal mucosa (left), and in normal tissue and CRC at different stages (right; 1-way ANOVA). (E) Kaplan-Meier analysis of overall survival and disease-free survival in cohort 2 (log-rank test). *P < 0.05, **P < 0.01, ***P < 0.001.